FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896774908> ?p ?o ?g. }

• W2896774908 endingPage "e475" @default.
• W2896774908 startingPage "e474" @default.
• W2896774908 abstract "NF1 is an autosomal dominant tumor predisposition syndrome. Malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma subtype that is the leading cause of death in people with NF1. There is limited information regarding outcomes of patients with NF1-associated MPNST, and specifically after radiation therapy (RT), a modality known to infrequently cause second cancers. As it is important to identify outcomes to aid in the selection of an optimal treatment paradigm for patients, our primary objective is to determine the local control (LC) rate in patients with NF1 who develop MPNST and are treated with RT. We also assessed overall survival (OS) and frequency of CTCAE toxicities following RT. We hypothesize that RT is an effective and safe treatment modality in patients with NF1 with MPNST. Data were collected through retrospective analysis of records of patients treated at our institution with the diagnosis of NF1 and pathologically-confirmed MPNST who underwent definitive RT from 2009-2017. Patients without follow-up or that had a history of previous RT to the affected area were excluded. Kaplan–Meier curves were used to estimate LC and OS rates. Fifteen patients (F=9, M=6) were identified with median age of 25 (range 10-38) years. The median follow-up was 29.1 (9.9-84.5) months. 47% of patients had tumors located in an extremity and 53% within the trunk. Four MPNSTs were <5 cm (27%), five 5-10 cm (33%) and six >10 cm (40%). All patients received initial therapy for a new diagnosis of MPNST, except one treated for recurrent disease after resection only. Patients were treated with several paradigms: 13% surgery + adjuvant RT, 33% surgery + adjuvant systemic therapy (ST) and RT, 40% neoadjuvant ST and RT + surgery, 7% interdigitated chemotherapy and neoadjuvant RT + surgery, 7% ST and RT. The median RT dose delivered was 50 Gy (44-63 Gy) via IMRT (87%), SBRT (7%), or 3D (7%). LC was estimated to be 100%, 91.7%, and 91.7% at 1, 3, and 5 years, and OS was identified as 100%, 79.2%, and 53.2% at 1, 3, and 5 years, respectively. Three patients progressed distantly (brain=2, lungs=1) and two developed second primaries (second MPNST, gliosarcoma). The most common toxicities at the end of RT were grade 1 fatigue and grade 1 pain (Table 1). No secondary malignancies within the radiation field were reported. In our study, therapeutic strategies that include RT resulted in excellent LC rates and were well tolerated for NF1-associated MPNST. Given the paucity of data about safety and efficacy of RT for NF1-associated MPNST, this dataset is encouraging, as outcomes were comparable to those reported for other types of soft tissue sarcomas. However, longer duration follow-up and larger cohorts are required to characterize the risk of second tumors and develop optimal approaches regarding timing and RT delivery.Abstract TU_22_3114; Table 1No. of Pts with CTCAE Toxicity (Grade)12345Fatigue73000Pain74000Dermatitis33000Paresthesia10000Anorexia30100Diarrhea10000Dysphagia10000Nausea21100Vomiting11100 Open table in a new tab" @default.
• W2896774908 created "2018-10-26" @default.
• W2896774908 creator A5010279785 @default.
• W2896774908 creator A5026013783 @default.
• W2896774908 creator A5028606825 @default.
• W2896774908 creator A5051287778 @default.
• W2896774908 creator A5058349149 @default.
• W2896774908 date "2018-11-01" @default.
• W2896774908 modified "2023-09-27" @default.
• W2896774908 title "Long-Term Outcomes of Radiation Therapy (RT) in the Management of Malignant Peripheral Nerve Sheath Tumors (MPNST) in Patients with Neurofibromatosis Type 1 (NF1)" @default.
• W2896774908 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1357" @default.
• W2896774908 hasPublicationYear "2018" @default.
• W2896774908 type Work @default.
• W2896774908 sameAs 2896774908 @default.
• W2896774908 citedByCount "6" @default.
• W2896774908 countsByYear W28967749082019 @default.
• W2896774908 countsByYear W28967749082021 @default.
• W2896774908 countsByYear W28967749082022 @default.
• W2896774908 countsByYear W28967749082023 @default.
• W2896774908 crossrefType "journal-article" @default.
• W2896774908 hasAuthorship W2896774908A5010279785 @default.
• W2896774908 hasAuthorship W2896774908A5026013783 @default.
• W2896774908 hasAuthorship W2896774908A5028606825 @default.
• W2896774908 hasAuthorship W2896774908A5051287778 @default.
• W2896774908 hasAuthorship W2896774908A5058349149 @default.
• W2896774908 hasBestOaLocation W28967749081 @default.
• W2896774908 hasConcept C126322002 @default.
• W2896774908 hasConcept C126838900 @default.
• W2896774908 hasConcept C141071460 @default.
• W2896774908 hasConcept C142724271 @default.
• W2896774908 hasConcept C143998085 @default.
• W2896774908 hasConcept C18903297 @default.
• W2896774908 hasConcept C2778173781 @default.
• W2896774908 hasConcept C2778256501 @default.
• W2896774908 hasConcept C2778984943 @default.
• W2896774908 hasConcept C2781197403 @default.
• W2896774908 hasConcept C2909023644 @default.
• W2896774908 hasConcept C509974204 @default.
• W2896774908 hasConcept C71924100 @default.
• W2896774908 hasConcept C86803240 @default.
• W2896774908 hasConceptScore W2896774908C126322002 @default.
• W2896774908 hasConceptScore W2896774908C126838900 @default.
• W2896774908 hasConceptScore W2896774908C141071460 @default.
• W2896774908 hasConceptScore W2896774908C142724271 @default.
• W2896774908 hasConceptScore W2896774908C143998085 @default.
• W2896774908 hasConceptScore W2896774908C18903297 @default.
• W2896774908 hasConceptScore W2896774908C2778173781 @default.
• W2896774908 hasConceptScore W2896774908C2778256501 @default.
• W2896774908 hasConceptScore W2896774908C2778984943 @default.
• W2896774908 hasConceptScore W2896774908C2781197403 @default.
• W2896774908 hasConceptScore W2896774908C2909023644 @default.
• W2896774908 hasConceptScore W2896774908C509974204 @default.
• W2896774908 hasConceptScore W2896774908C71924100 @default.
• W2896774908 hasConceptScore W2896774908C86803240 @default.
• W2896774908 hasIssue "3" @default.
• W2896774908 hasLocation W28967749081 @default.
• W2896774908 hasOpenAccess W2896774908 @default.
• W2896774908 hasPrimaryLocation W28967749081 @default.
• W2896774908 hasRelatedWork W1973735103 @default.
• W2896774908 hasRelatedWork W2005451880 @default.
• W2896774908 hasRelatedWork W2058489177 @default.
• W2896774908 hasRelatedWork W2106647764 @default.
• W2896774908 hasRelatedWork W2136934903 @default.
• W2896774908 hasRelatedWork W2322559635 @default.
• W2896774908 hasRelatedWork W2733816167 @default.
• W2896774908 hasRelatedWork W2896774908 @default.
• W2896774908 hasRelatedWork W3117905107 @default.
• W2896774908 hasRelatedWork W2335953591 @default.
• W2896774908 hasVolume "102" @default.
• W2896774908 isParatext "false" @default.
• W2896774908 isRetracted "false" @default.
• W2896774908 magId "2896774908" @default.
• W2896774908 workType "article" @default.